Proteomic signatures associated with p53 mutational status in lung adenocarcinoma

Proteomics

Volumn 14, Issue 23-24, 2014, Pages 2750-2759

  Taguchi, Ayumu ^a   Delgado, Oliver ^a   Çeliktaş, Müge ^a   Katayama, Hiroyuki ^a   Wang, Hong ^a   Gazdar, Adi F ^b   Hanash, Samir M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Lung adenocarcinoma; P53; PGC 1 ; Systems Biology; Transcriptomics

Indexed keywords

MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PROTEIN P53; SMALL INTERFERING RNA;

ADULT; AGED; ARTICLE; BIOGENESIS; BIOINFORMATICS; CELL ADHESION; CELL LINE; CELL PROLIFERATION; CLINICAL ARTICLE; CULTURE MEDIUM; FEMALE; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; INTRACELLULAR SPACE; LUNG ADENOCARCINOMA; MALE; MISSENSE MUTATION; MITOCHONDRION; OXIDATIVE PHOSPHORYLATION; PROTEIN ANALYSIS; STROMA CELL; ADENOCARCINOMA; GENETICS; LUNG TUMOR; METABOLISM; MUTATION; PROCEDURES; PROTEOMICS;

ADENOCARCINOMA; HUMANS; LUNG NEOPLASMS; MUTATION; PROTEOMICS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84913573550     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.201400378     Document Type: Article

References (47)

1. Vousden, K. H., Prives, C., Blinded by the light: the growing complexity of p53. Cell 2009, 137, 413-431.
2. Kandoth, C., McLellan, M. D., Vandin, F., Ye, K. et al., Mutational landscape and significance across 12 major cancer types. Nature 2013, 502, 333-339.
3. Muller, P. A., Vousden, K. H., Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer Cell 2014, 25, 304-317.
4. Muller, P. A., Vousden, K. H., p53 mutations in cancer. Nat. Cell Biol. 2013, 15, 2-8.
5. Imielinski, M., Berger, A. H., Hammerman, P. S., Hernandez, B. et al., Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 2012, 150, 1107-1120.
6. Wade, M., Li, Y. C., Wahl, G. M., MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat. Rev. Cancer 2013, 13, 83-96.
7. Xue, Q., Sano, T., Kashiwabara, K., Saito, M. et al., Aberrant expression of pRb, p16, p14ARF, MDM2, p21 and p53 in stage I adenocarcinomas of the lung. Pathol. Int. 2002, 52, 103-109.
8. Eymin, B., Gazzeri, S., Brambilla, C., Brambilla, E., Mdm2 overexpression and p14(ARF) inactivation are two mutually exclusive events in primary human lung tumors. Oncogene 2002, 21, 2750-2761.
9. Higashiyama, M., Doi, O., Kodama, K., Yokouchi, H. et al., MDM2 gene amplification and expression in non-small-cell lung cancer: immunohistochemical expression of its protein is a favourable prognostic marker in patients without p53 protein accumulation. Br. J. Cancer 1997, 75, 1302-1308.
10. Momand, J., Jung, D., Wilczynski, S., Niland, J., The MDM2 gene amplification database. Nucl. Acids Res. 1998, 26, 3453-3459.
11. Tam, K. W., Zhang, W., Soh, J., Stastny, V. et al., CDKN2A/p16 inactivation mechanisms and their relationship to smoke exposure and molecular features in non-small-cell lung cancer. J. Thorac. Oncol. 2013, 8, 1378-1388.
12. Zhang, Y., Xiong, Y., Yarbrough, W. G., ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 1998, 92, 725-734.
13. Mandinova, A., Lee, S. W., The p53 pathway as a target in cancer therapeutics: obstacles and promise. Sci. Transl. Med. 2011, 3, 64rv61.
14. Janicke, R. U., Sohn, D., Schulze-Osthoff, K., The dark side of a tumor suppressor: anti-apoptotic p53. Cell Death Differ. 2008, 15, 959-976.
15. Wang, Y. C., Lin, R. K., Tan, Y. H., Chen, J. T., Chen, C. Y., Wild-type p53 overexpression and its correlation with MDM2 and p14ARF alterations: an alternative pathway to non-small-cell lung cancer. J. Clin. Oncol. 2005, 23, 154-164.
16. Koga, T., Hashimoto, S., Sugio, K., Yoshino, I. et al., Heterogeneous distribution of P53 immunoreactivity in human lung adenocarcinoma correlates with MDM2 protein expression, rather than with P53 gene mutation. Int. J. Cancer 2001, 95, 232-239.
17. Taguchi, A., Politi, K., Pitteri, S. J., Lockwood, W. W. et al., Lung cancer signatures in plasma based on proteome profiling of mouse tumor models. Cancer Cell 2011, 20, 289-299.
18. Faca, V. M., Ventura, A. P., Fitzgibbon, M. P., Pereira-Faca, S. R. et al., Proteomic analysis of ovarian cancer cells reveals dynamic processes of protein secretion and shedding of extra-cellular domains. PloS One 2008, 3, e2425.
19. Ong, S. E., Mann, M., A practical recipe for stable isotope labeling by amino acids in cell culture (SILAC). Nat. Protoc. 2006, 1, 2650-2660.
20. Inal, J. M., Kosgodage, U., Azam, S., Stratton, D. et al., Blood/plasma secretome and microvesicles. Biochim. Biophys. Acta 2013, 1834, 2317-2325.
21. Girnun, G. D., The diverse role of the PPARgamma coactivator 1 family of transcriptional coactivators in cancer. Semin. Cell Dev. Biol. 2012, 23, 381-388.
22. Thiery, J. P., Acloque, H., Huang, R. Y., Nieto, M. A., Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139, 871-890.
23. Ogunwobi, O. O., Liu, C., Hepatocyte growth factor upregulation promotes carcinogenesis and epithelial-mesenchymal transition in hepatocellular carcinoma via Akt and COX-2 pathways. Clin. Exp. Metastasis 2011, 28, 721-731.
24. Neilsen, P. M., Noll, J. E., Mattiske, S., Bracken, C. P. et al., Mutant p53 drives invasion in breast tumors through up-regulation of miR-155. Oncogene 2013, 32, 2992-3000.
25. Ikushima, H., Miyazono, K., TGFbeta signalling: a complex web in cancer progression. Nat. Rev. Cancer 2010, 10, 415-424.
26. O'Connell, M. P., Fiori, J. L., Xu, M., Carter, A. D. et al., The orphan tyrosine kinase receptor, ROR2, mediates Wnt5A signaling in metastatic melanoma. Oncogene 2010, 29, 34-44.
27. Ren, D. Y., Minami, Y., Nishita, M., Critical role of Wnt5a-Ror2 signaling in motility and invasiveness of carcinoma cells following Snail-mediated epithelial-mesenchymal transition. Genes Cells 2011, 16, 304-315.
28. Morioka, K., Tanikawa, C., Ochi, K., Daigo, Y. et al., Orphan receptor tyrosine kinase ROR2 as a potential therapeutic target for osteosarcoma. Cancer Sci. 2009, 100, 1227-1233.
29. Edris, B., Espinosa, I., Muhlenberg, T., Mikels, A. et al., ROR2 is a novel prognostic biomarker and a potential therapeutic target in leiomyosarcoma and gastrointestinal stromal tumour. J. Pathol. 2012, 227, 223-233.
30. Li, C. G., Chen, H. Y., Hu, L. Y., Xing, Y. M. et al., Ror2 modulates the canonical Wnt signaling in lung epithelial cells through cooperation with Fzd2. BMC Mol. Biol. 2008, 9.
31. Yamamoto, H., Oue, N., Sato, A., Hasegawa, Y. et al., Wnt5a signaling is involved in the aggressiveness of prostate cancer and expression of metalloproteinase. Oncogene 2010, 29, 2036-2046.
32. Vousden, K. H., Ryan, K. M., p53 and metabolism. Nat. Rev. Cancer 2009, 9, 691-700.
33. Matoba, S., Kang, J. G., Patino, W. D., Wragg, A. et al., p53 regulates mitochondrial respiration. Science 2006, 312, 1650-1653.
34. Aquilano, K., Baldelli, S., Pagliei, B., Cannata, S. M. et al., p53 orchestrates the PGC-1alpha-mediated antioxidant response upon mild redox and metabolic imbalance. Antioxid. Redox Signal. 2013, 18, 386-399.
35. Sahin, E., Colla, S., Liesa, M., Moslehi, J. et al., Telomere dysfunction induces metabolic and mitochondrial compromise. Nature 2011, 470, 359-365.
36. D'Errico, I., Salvatore, L., Murzilli, S., Lo Sasso, G. et al., Peroxisome proliferator-activated receptor-gamma coactivator 1-alpha (PGC1alpha) is a metabolic regulator of intestinal epithelial cell fate. Proc. Nat. Acad. Sci. USA 2011, 108, 6603-6608.
37. Bhalla, K., Hwang, B. J., Dewi, R. E., Ou, L. et al., PGC1alpha promotes tumor growth by inducing gene expression programs supporting lipogenesis. Cancer Res. 2011, 71, 6888-6898.
38. Vazquez, F., Lim, J. H., Chim, H., Bhalla, K. et al., PGC1alpha expression defines a subset of human melanoma tumors with increased mitochondrial capacity and resistance to oxidative stress. Cancer Cell 2013, 23, 287-301.
39. Klimcakova, E., Chenard, V., McGuirk, S., Germain, D. et al., PGC-1alpha promotes the growth of ErbB2/Neu-induced mammary tumors by regulating nutrient supply. Cancer Res. 2012, 72, 1538-1546.
40. Sen, N., Satija, Y. K., Das, S., PGC-1alpha, a key modulator of p53, promotes cell survival upon metabolic stress. Mol. Cell 2011, 44, 621-634.
41. Funes, J. M., Quintero, M., Henderson, S., Martinez, D. et al., Transformation of human mesenchymal stem cells increases their dependency on oxidative phosphorylation for energy production. Proc. Natl. Acad. Sci. USA 2007, 104, 6223-6228.
42. Weinberg, F., Hamanaka, R., Wheaton, W. W., Weinberg, S. et al., Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc. Natl. Acad. Sci. USA 2010, 107, 8788-8793.
43. Fiori, M. E., Barbini, C., Haas, T. L., Marroncelli, N. et al., Antitumor effect of miR-197 targeting in p53 wild-type lung cancer. Cell Death Differ. 2014, 21, 774-782.
44. Meijer, A., Kruyt, F. A., van der Zee, A. G., Hollema, H. et al., Nutlin-3 preferentially sensitises wild-type p53-expressing cancer cells to DR5-selective TRAIL over rhTRAIL. Br. J. Cancer 2013, 109, 2685-2695.
45. Kulke, M. H., Chan, J. A., Meyerhardt, J. A., Zhu, A. X. et al., A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid tumors. Cancer Chemother. Pharmacol. 2011, 68, 293-300.
46. Harrison, M. R., Hahn, N. M., Pili, R., Oh, W. K. et al., A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal(R) dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC). Invest. New Drugs 2011, 29, 1465-1474.
47. Zhou, Q., Gustafson, D., Nallapareddy, S., Diab, S. et al., A phase I dose-escalation, safety and pharmacokinetic study of the 2-methoxyestradiol analog ENMD-1198 administered orally to patients with advanced cancer. Invest. New Drugs 2011, 29, 340-346.